{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:25:43Z","timestamp":1759227943964},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1007\/s11908-007-0069-1","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T17:18:09Z","timestamp":1205774289000},"page":"448-456","source":"Crossref","is-referenced-by-count":15,"title":["Combination antifungal therapy for the treatment of invasive yeast and mold infections"],"prefix":"10.1007","volume":"9","author":[{"given":"John W.","family":"Baddley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,18]]},"reference":[{"key":"69_CR1","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1001\/jama.1979.03290480052025","volume":"241","author":"S.D. Codish","year":"1979","unstructured":"Codish SD, Tobias JS, Hannigan M: Combined amphotericin B-flucytosine therapy in aspergillus pneumonia. JAMA 1979, 241:2418\u20132419.","journal-title":"JAMA"},{"key":"69_CR2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","volume":"301","author":"J.E. Bennett","year":"1979","unstructured":"Bennett JE, Dismukes WE, Duma RJ, et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126\u2013131.","journal-title":"N Engl J Med"},{"key":"69_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJM198708063170602","volume":"317","author":"W.E. Dismukes","year":"1987","unstructured":"Dismukes WE, Cloud G, Gallis HA, et al.: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334\u2013341.","journal-title":"N Engl J Med"},{"key":"69_CR4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","volume":"337","author":"C. Horst van der","year":"1997","unstructured":"van der Horst C, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15\u201321.","journal-title":"N Engl J Med"},{"key":"69_CR5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1300\/J100v03n04_04","volume":"3","author":"R.E. Lewis","year":"1999","unstructured":"Lewis RE, Klepser ME, Pfaller MA: Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. J Infect Dis Pharmacother 1999, 3:61\u201384.","journal-title":"J Infect Dis Pharmacother"},{"key":"69_CR6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","volume":"48","author":"M.D. Johnson","year":"2004","unstructured":"Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al.: Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693\u2013715.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR7","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.2165\/00003495-200565110-00002","volume":"65","author":"J.W. Baddley","year":"2005","unstructured":"Baddley JW, Pappas PG: Combination antifungal therapy: clinical potential. Drugs 2005, 65:1461\u20131480.","journal-title":"Drugs"},{"issue":"8pt2","key":"69_CR8","doi-asserted-by":"crossref","first-page":"149S","DOI":"10.1592\/phco.21.12.149S.34505","volume":"21","author":"R.E. Lewis","year":"2001","unstructured":"Lewis RE, Kontoyiannis DP: Rationale for combination antifungal therapy. Pharmacotherapy 2001, 21(8 pt 2):149S\u2013164S.","journal-title":"Pharmacotherapy"},{"key":"69_CR9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1086\/496935","volume":"41","author":"S.K. Fridkin","year":"2005","unstructured":"Fridkin SK: The changing face of fungal infections in health care settings. Clin Infect Dis 2005, 41:1455\u20131460.","journal-title":"Clin Infect Dis"},{"key":"69_CR10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/49.2.345","volume":"49","author":"R.E. Lewis","year":"2002","unstructured":"Lewis RE, Diekema DJ, Messer SA, et al.: Comparison of Etest, checquerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother 2002, 49:345\u2013351.","journal-title":"J Antimicrob Chemother"},{"key":"69_CR11","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1128\/AAC.39.11.2459","volume":"39","author":"M.A. Ghannoum","year":"1995","unstructured":"Ghannoum MA, Fu AY, Ibrahim AS, et al.: In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995, 39:2459\u20132465.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0732-8893(01)00297-8","volume":"14","author":"D.J. Keele","year":"2001","unstructured":"Keele DJ, DeLallo VC, Lewis RE, et al.: Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2001, 14:121\u2013126.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"69_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000237753","volume":"24","author":"A. Polak","year":"1978","unstructured":"Polak A: Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 1978, 24:2\u201316.","journal-title":"Chemotherapy"},{"key":"69_CR14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/AAC.22.5.763","volume":"22","author":"F.C. Odds","year":"1982","unstructured":"Odds FC: Interactions among amphotericin B, 5-flurocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982, 22:763\u2013770.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/infdis\/146.2.138","volume":"146","author":"J. Brajtburg","year":"1982","unstructured":"Brajtburg J, Kobayashi D, Medoff G, et al.: Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis 1982, 146:138\u2013146.","journal-title":"J Infect Dis"},{"key":"69_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0732-8893(02)00361-9","volume":"43","author":"E. Roling","year":"2002","unstructured":"Roling E, Klepser ME, Wasson A, et al.: Antifungal activities of fluconazole and caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans. Diagn Microbiol Infect Dis 2002, 43:13\u201317.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"69_CR17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/158.1.80","volume":"158","author":"M. Thaler","year":"1988","unstructured":"Thaler M, Bacher J, O\u2019Leary T, et al.: Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia. J Infect Dis 1988, 158:80\u201388.","journal-title":"J Infect Dis"},{"key":"69_CR18","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1128\/AAC.39.3.598","volume":"39","author":"A.M. Sugar","year":"1995","unstructured":"Sugar AM, Hitchcock CA, Troke PF, et al.: Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995, 39:598\u2013601.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jac\/dkl395","volume":"58","author":"M. Marine","year":"2006","unstructured":"Marine M, Serena C, Pastor FJ, et al.: Combined antifungal therapy in a murine infection by Candida. J Antimicrob Chemother 2006, 58:1295\u20131298.","journal-title":"J Antimicrob Chemother"},{"key":"69_CR20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","volume":"38","author":"P.G. Pappas","year":"2004","unstructured":"Pappas PG, Rex JH, Sobel JD, et al.: Guidelines for treatment of candidiasis. Clin Infect Dis 2004, 38:161\u2013189.","journal-title":"Clin Infect Dis"},{"key":"69_CR21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/BF01713042","volume":"24","author":"M. Abele-Horn","year":"1996","unstructured":"Abele-Horn M, Kopp A, Sternberg U, et al.: A randomized study comparing fluconazole with amphotericin B\/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996, 24:426\u2013432.","journal-title":"Infection"},{"key":"69_CR22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","volume":"36","author":"J.H. Rex","year":"2003","unstructured":"Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221\u20131228.","journal-title":"Clin Infect Dis"},{"key":"69_CR23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s10096-005-0024-8","volume":"24","author":"L. Ostrosky-Zeichner","year":"2005","unstructured":"Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005, 24:662\u2013664.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"69_CR24","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/AAC.47.7.2208-2216.2003","volume":"47","author":"R.C. Matthews","year":"2003","unstructured":"Matthews RC, Rigg G, Hodgetts S, et al.: Preclinical assessment of the clinical efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother. 2003, 47:2208\u20132216.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/503428","volume":"42","author":"J. Pachl","year":"2006","unstructured":"Pachl J, Svoboda P, Jacobs F, et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006, 42:1404\u20131413.","journal-title":"Clin Infect Dis"},{"key":"69_CR26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/44.1.65","volume":"44","author":"F. Barchiesi","year":"1999","unstructured":"Barchiesi F, Gallo D, Caselli F, et al.: In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999, 44:65\u201370.","journal-title":"J Antimicrob Chemother"},{"key":"69_CR27","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.44.9.2435-2441.2000","volume":"44","author":"F. Barchiesi","year":"2000","unstructured":"Barchiesi F, Schimizzi AM, Caselli F, et al.: Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44:2435\u20132441.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinids\/2.4.551","volume":"2","author":"J.R. Graybill","year":"1980","unstructured":"Graybill JR, Williams M, Van Cutsem E, et al.: Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole. Rev Infect Dis 1980, 2:551\u2013558.","journal-title":"Rev Infect Dis"},{"key":"69_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1128\/AAC.41.2.331","volume":"41","author":"S.P. Franzot","year":"1997","unstructured":"Franzot SP, Casadevall A: Pneumocandin L-743, 872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997, 41:331\u2013336.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/BF00158577","volume":"8","author":"A.J. Bava","year":"1992","unstructured":"Bava AJ, Negroni R: Comparative study of six antifungal treatments in an experimental model of murine cryptococcosis. Eur J Epidemiol 1992, 8:422\u2013426.","journal-title":"Eur J Epidemiol"},{"key":"69_CR31","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000238138","volume":"28","author":"A. Polak","year":"1982","unstructured":"Polak, A, Scholer HJ, Wall M: Combination therapy of experimental candidiasis, cryptococcosis, and aspergillosis in mice. Chemotherapy 1982, 28:461\u2013479.","journal-title":"Chemotherapy"},{"key":"69_CR32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/AAC.41.7.1589","volume":"41","author":"J.C. Ding","year":"1997","unstructured":"Ding JC, Bauer M, Diamond DM, et al.: Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997, 41:1589\u20131593.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR33","unstructured":"Larsen RA, Bauer M, Thomas AM, et al.: Amphotericin B combined with fluconazole is better than all other combinations for cryptococcal meningitis [abstract 17]. Presented at the Focus on Fungal Infections 12 Meeting. Phoenix, AR; March 20\u201322, 2002."},{"key":"69_CR34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","volume":"30","author":"M.S. Saag","year":"2000","unstructured":"Saag MS, Graybill RJ, Larsen RA, et al.: Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710\u2013718.","journal-title":"Clin Infect Dis"},{"key":"69_CR35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.7326\/0003-4819-113-3-183","volume":"113","author":"R.A. Larsen","year":"1990","unstructured":"Larsen RA, Leal ME, Chan LS: Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990, 113:183\u2013187.","journal-title":"Ann Intern Med"},{"key":"69_CR36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199201093260202","volume":"326","author":"M.S. Saag","year":"1992","unstructured":"Saag MS, Powderly WG, Cloud GA, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83\u201389.","journal-title":"N Engl J Med"},{"key":"69_CR37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/515110","volume":"28","author":"M.S. Saag","year":"1999","unstructured":"Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:291\u2013296.","journal-title":"Clin Infect Dis"},{"key":"69_CR38","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/clinids\/19.4.741","volume":"19","author":"R.A. Larsen","year":"1994","unstructured":"Larsen RA, Bozzette SA, Jones BE, et al.: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741\u2013745.","journal-title":"Clin Infect Dis"},{"key":"69_CR39","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"A.E. Brouwer","year":"2004","unstructured":"Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination therapies for HIV associated cryptococcal meningitis: a randomized trial. Lancet 2004, 363:1764\u20131767.","journal-title":"Lancet"},{"key":"69_CR40","unstructured":"Pappas PG, Larsen RA, Chenkostad P, et al.: Combination amphotericin B plus fluconazole versus amphotericin B alone for treatment of acute cryptococcal meningitis [abstract]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 17\u201320, 2007."},{"key":"69_CR41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R. Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New Engl J Med 2002, 347:408\u2013415.","journal-title":"New Engl J Med"},{"key":"69_CR42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","volume":"44","author":"T.J. Walsh","year":"2007","unstructured":"Walsh TJ, Raad I, Patterson TG, et al.: Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2\u201312.","journal-title":"Clin Infect Dis"},{"key":"69_CR43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","volume":"39","author":"J. Maertens","year":"2004","unstructured":"Maertens J, Raad I, Petrikkos G, et al.: Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients reftactory to on intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563\u20131571.","journal-title":"Clin Infect Dis"},{"key":"69_CR44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jinf.2006.03.003","volume":"53","author":"D.W. Denning","year":"2006","unstructured":"Denning DW, Marr Ka, Lau WM, et al.: Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006, 53:337\u2013349.","journal-title":"J Infect"},{"key":"69_CR45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0732-8893(92)90053-V","volume":"15","author":"D.W. Denning","year":"1992","unstructured":"Denning DW, Hanson LA, Perlman AM, et al.: In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992, 15:21\u201334.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"69_CR46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/506617","volume":"194","author":"J. Meletiadis","year":"2006","unstructured":"Meletiadis J, Petraitis V, Petratiene R, et al.: Triazole-polyene antagonism in experimental pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006, 194:1008\u20131018.","journal-title":"J Infect Dis"},{"key":"69_CR47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1128\/AAC.46.1.245-247.2002","volume":"46","author":"S. Arikan","year":"2002","unstructured":"Arikan S, Lozano-Chiu M, Paetznik V, et al.: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245\u2013247.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR48","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1128\/AAC.46.9.3039-3041.2002","volume":"46","author":"S.G. Perea","year":"2002","unstructured":"Perea SG, Gonzalez G, Fothergill AW, et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039\u20133041.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl2","key":"69_CR49","first-page":"45S","volume":"31","author":"A. Polak","year":"1988","unstructured":"Polak A: Combination therapy with antifungal drugs. Mycoses 1988, 31(Suppl 2):45S\u201353S.","journal-title":"Mycoses"},{"key":"69_CR50","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1128\/AAC.49.12.4867-4875.2005","volume":"49","author":"K.V. Clemons","year":"2005","unstructured":"Clemons KV, Espiritu M, Parmar R, et al.: Comparative efficacies of conventional amphotericin b, liposomal amphotericin b (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against murine cental nervous system aspergillosis. Antimicrob Agents Chemother 2005, 49:4867\u20134875.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR51","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1086\/375420","volume":"187","author":"V. Petraitis","year":"2003","unstructured":"Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. Journal Infect Dis 2003, 187:1834\u20131843.","journal-title":"Journal Infect Dis"},{"key":"69_CR52","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1128\/AAC.46.8.2564-2568.2002","volume":"46","author":"W.R. Kirkpatrick","year":"2002","unstructured":"Kirkpatrick WR, Perea S, Coco BJ, et al.: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564\u20132568.","journal-title":"Antimicrob Agents Chemother"},{"key":"69_CR53","unstructured":"Petraitis V, Petraitiene R, Legit RJ, et al.: Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis [abstract 2003]. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco; September 26\u201329, 1999."},{"key":"69_CR54","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1086\/313756","volume":"30","author":"D.A. Stevens","year":"2000","unstructured":"Stevens DA, Kan VL, Judson MA, et al.: Practice guidelines for disease caused by Aspergillus. Clin Infect Dis 2000, 30:696\u2013709.","journal-title":"Clin Infect Dis"},{"key":"69_CR55","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1002\/cncr.11115","volume":"97","author":"T.B. Aliff","year":"2003","unstructured":"Aliff TB, Maslak PG, Jurcic JG, et al.: Refractory aspergillus pneumonia in patients with acute leukemia. Cancer 2003, 97:1025\u20131032.","journal-title":"Cancer"},{"key":"69_CR56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cncr.11479","volume":"98","author":"D.P. Kontoyiannis","year":"2003","unstructured":"Kontoyiannis DP, Hachen R, Lewis RE, et al.: Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292\u2013299.","journal-title":"Cancer"},{"key":"69_CR57","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/423380","volume":"39","author":"K.A. Marr","year":"2004","unstructured":"Marr KA, Boeckth M, Carter RA, et al.: Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004, 39:797\u2013802.","journal-title":"Clin Infect Dis"},{"key":"69_CR58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","volume":"81","author":"N. Singh","year":"2006","unstructured":"Singh N, Limaye AP, Forrest G, et al.: Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006, 81:320\u2013326.","journal-title":"Transplantation"},{"issue":"Suppl3","key":"69_CR59","first-page":"188S","volume":"37","author":"W.J. Steinbach","year":"2002","unstructured":"Steinbach WJ, Stevens DA, Denning DW: Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2002, 37(Suppl 3):188S\u2013224S.","journal-title":"Clin Infect Dis"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-007-0069-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-007-0069-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-007-0069-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:22:07Z","timestamp":1559434927000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-007-0069-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1007\/s11908-007-0069-1","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}